>Marché du traitement de l'anthrax au Moyen-Orient et en Afrique, par type ( anthrax cutané , anthrax pulmonaire et anthrax intestinal), voie d'administration (orale, parentérale et autres), utilisateur final (organisation gouvernementale, hôpitaux, instituts universitaires et de recherche, et autres) Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché du traitement de l'anthrax au Moyen-Orient et en Afrique
Le marché du traitement de l'anthrax au Moyen-Orient et en Afrique est stimulé par des facteurs tels que l'incidence croissante des infections bactériennes , l'augmentation du financement de la recherche et le développement de nouvelles thérapies pour le traitement de l'anthrax et les produits en cours de développement qui augmentent sa demande ainsi que l'augmentation des investissements dans la recherche et le développement conduisent à la croissance du marché. Actuellement, les dépenses de santé ont augmenté dans les pays développés et émergents, ce qui devrait créer un avantage concurrentiel pour les fabricants afin de développer des produits nouveaux et innovants.
L'augmentation du nombre de personnes souffrant de l'anthrax dans le monde est l'un des principaux facteurs de croissance du marché du traitement de l'anthrax. L'augmentation du soutien financier aux chercheurs pour le développement de nouvelles interventions et l'augmentation de la menace d'exposition au Bacillus anthracis parmi les populations civiles et les forces militaires accélèrent la croissance du marché. L'augmentation du nombre de programmes de recherche et développement et l'augmentation des partenariats public-privé pour faciliter les développements de nouveaux traitements innovants et efficaces influencent davantage le marché. Cependant, le coût élevé associé au traitement et à la procédure ainsi que les réglementations gouvernementales strictes pour l'approbation des produits devraient entraver la croissance du marché du traitement de l'anthrax.
Le rapport sur le marché du traitement de l'anthrax au Moyen-Orient et en Afrique fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché , les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité. L'évolutivité et l'expansion commerciale des unités de vente au détail dans les pays en développement de diverses régions et le partenariat avec les fournisseurs pour une distribution sûre de machines et de produits pharmaceutiques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Le marché du traitement de l'anthrax au Moyen-Orient et en Afrique est favorable et vise à réduire la progression de la maladie. Data Bridge Market Research analyse que le marché du traitement de l'anthrax au Moyen-Orient et en Afrique connaîtra un TCAC de 8,6 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others),End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) Industry Trends and Forecast to 2029 |
|
Countries Covered |
Saudi Arabia, South Africa, U.A.E, Israel, Egypt, Rest of Middle East and Africa |
|
Market Players Covered |
Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., Lupin, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, among others |
Middle East and Africa Anthrax Treatment Market Dynamics
Market Definition
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, erebrospinal fluid, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Drivers
- Increasing Prevalence of Anthrax Infections
The incidence of bacterial infections is increasing worldwide. Anthrax is a bacterial infection caused by Bacillus anthracis which is an aerobic, gram-positive spore-forming bacterium. Depending on the route of entry of B. anthracis spores, it occurs primarily as a cutaneous, pulmonary, or gastrointestinal infection. A characteristic black, crusty spot develops on the affected skin area later and, after a few weeks, begins to loosen and ultimately falls off, leaving a scar. The course of these events is so characteristic that the diagnosis is not often missed by physicians familiar with the disease, even though it is rare. Pulmonary anthrax is the most lethal of the three types of anthrax in which, the spores once inhaled germinate within the tracheobronchial lymph nodes and multiply. Anthrax is a harmful disease that affects both humans and animals. It is a life-threatening infection caused by Bacillus anthracis. Thus, this increasing incidence and prevalence of anthrax infections has developed a need of more diagnostic approaches with increased sensitivity that can detect infection in low volume.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of anthrax treatment market. The increase in the financial support to the researchers for developing novel intervention, and rise in threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and rise in public-private partnerships for facilitating novel developments for the innovative and effective treatment further influence the market.
- Increasing Research Funding and the development of novel therapies for anthrax treatment population
Research and development is a prerequisite in order to modify the procedure intended to treat different kinds of patients. The demand of anthrax treatment is increasing worldwide involving every country. This is why the companies are continuously focusing towards research and development in order to achieve success in providing effective treatment to patients. In these recent years many diagnostic approaches have come forward to take diagnosis to new steps, and many are being made to detect even the lowest volume of parasite in human body.
These new approaches in diagnosis will take the market forward. With the increase in research funding and the development of novel therapies for the treatment of anthrax. There are several novel and pre-existing antibiotics, as well as toxin inhibitors that have shown increasing promise that targets both bacterial growth as well as toxin production for effectively work against anthrax bacterium.
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the Middle East and Africa anthrax treatment market growth
Opportunities
- Rising product launch
Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.
Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the Middle East and Africa market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.
Restraints/Challenges
- High cost of treatment
The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.
Moreover, asymptomatic infections have to go through very specific tests for the identification of bacteria which are costly. Since the high cost of diagnosis for the anthrax, it is expected to restrain the market growth. As the cost of identification treatments is too high, it restricts physicians and patients to accommodate a high-quality and effective solution. Henceforth, the high cost of the treatment procedures has a negative impact on the cost of the overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that high-cost procedures are expected to act as a restraint on the Middle East and Africa anthrax treatment market growth.
Recent Development
- In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 which is a new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age with recommended antibacterial drugs.
- In January 2022, Alembic Pharmaceuticals Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg which is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This results in expansion of product portfolio of the company.
Middle East and Africa Anthrax Treatment Market Segmentation
Middle East and Africa anthrax treatment market is categorized into three notable segments based on type, route of administration and end user. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of type, the Middle East and Africa anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.
Route of Administration
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of route of administration, Middle East and Africa anthrax treatment market is segmented into oral, parenteral and others.
End User
- Government Organization
- Hospitals
- Academic and Research Institutes,
- Others
On the basis of end user, Middle East and Africa anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.
Anthrax Treatment Market Regional Analysis/Insights
The Middle East and Africa anthrax treatment market is analysed and market size insights and trends are provided by type, route of administration and end user as referenced above.
The countries covered in the anthrax treatment report are Saudi Arabia, South Africa, U.A.E, Israel, Egypt, Rest of Middle East and Africa.
L’Afrique du Sud devrait dominer le marché en raison des progrès technologiques croissants dans les régions en développement.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et des routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du traitement de l'anthrax
Le paysage concurrentiel du marché du traitement de l'anthrax au Moyen-Orient et en Afrique fournit des détails par concurrents. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché du traitement de l'anthrax.
Certains acteurs du marché sont Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., Lupin, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse des parts de marché du Moyen-Orient et de l'Afrique par rapport aux régions et des fournisseurs. Veuillez demander un appel à l'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 DEMOGRAPHIC TRENDS-
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS-
4.4.1 INCIDENCE
4.4.2 DEVELOPED COUNTRIES-
4.4.3 DEVELOPING COUNTRIES-
4.5 PATIENT ENROLMENT STRATEGIES-
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION-
4.7 CURRENT STATE OF ANTHRAX VACCINES
4.8 MIDDLE EAST & AFRICA ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018.
4.9 MIDDLE EAST & AFRICA ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION-
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR’S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY’S PIPELINE FOR ANTHRAX TREATMENT.
6 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT
7.2.2 FALSE DATA INTERPRETATION
7.3 OPPORTUNITIES
7.3.1 RISING PRODUCT LAUNCHES
7.3.2 RISING GOVERNMENT INITIATIVES
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
7.4 CHALLENGES
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION
7.4.2 LACK OF SKILLED PROFESSIONALS
8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 CUTANEOUS ANTHRAX
8.2.1 ANTIBIOTICS
8.2.1.1 BY DRUGS
8.2.1.1.1 CIPROFLOXACIN
8.2.1.1.2 LEVOFLOXACIN
8.2.1.1.3 DOXYCYCLINE
8.2.1.1.4 AMPICILLIN
8.2.1.1.5 OTHERS
8.2.1.2 BY PRODUCT TYPES
8.2.1.2.1 GENERICS
8.2.1.2.2 BRANDED
8.2.1.2.2.1 CIPRO
8.2.1.2.2.2 LEVO
8.2.1.2.2.3 DOXY
8.2.1.2.2.4 AMPICI
8.2.1.2.2.5 OTHERS
8.2.2 ANTITOXINS
8.2.2.1 RAXIBACUMAB
8.2.2.2 OBILTOXAXIMAB (ANTHIM)
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.2.2.4 OTHERS
8.2.3 VACCINES
8.2.3.1 RAXIBACUMAB
8.2.4 SURGERY
8.3 PULMONARY ANTHRAX
8.3.1 ANTIBIOTICS
8.3.1.1 BY DRUGS
8.3.1.1.1 CIPROFLOXACIN
8.3.1.1.2 LEVOFLOXACIN
8.3.1.1.3 DOXYCYCLINE
8.3.1.1.4 AMPICILLIN
8.3.1.1.5 OTHERS
8.3.1.2 BY PRODUCT TYPES
8.3.1.2.1 GENERICS
8.3.1.2.2 BRANDED
8.3.1.2.2.1 CIPRO
8.3.1.2.2.2 LEVO
8.3.1.2.2.3 DOXY
8.3.1.2.2.4 AMPICI
8.3.1.2.2.5 OTHERS
8.3.2 ANTITOXINS
8.3.2.1 RAXIBACUMAB
8.3.2.2 OBILTOXAXIMAB (ANTHIM)
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.3.2.4 OTHERS
8.3.3 VACCINES
8.3.3.1 RAXIBACUMAB
8.3.3.2 SURGERY
8.4 INTESTINAL ANTHRAX
8.4.1 ANTIBIOTICS
8.4.1.1 BY DRUGS
8.4.1.1.1 CIPROFLOXACIN
8.4.1.1.2 LEVOFLOXACIN
8.4.1.1.3 DOXYCYCLINE
8.4.1.1.4 AMPICILLIN
8.4.1.1.5 OTHERS
8.4.1.2 BY PRODUCT TYPES
8.4.1.2.1 GENERICS
8.4.1.2.2 BRANDED
8.4.1.2.2.1 CIPRO
8.4.1.2.2.2 LEVO
8.4.1.2.2.3 DOXY
8.4.1.2.2.4 AMPICI
8.4.1.2.2.5 OTHERS
8.4.2 ANTITOXINS
8.4.2.1 RAXIBACUMAB
8.4.2.2 OBILTOXAXIMAB (ANTHIM)
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.4.2.4 OTHERS
8.4.3 VACCINES
8.4.3.1 RAXIBACUMAB
8.4.3.2 SURGERY
9 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 PARENTERAL
9.3 ORAL
9.4 OTHERS
10 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY END USER
10.1 OVERVIEW
10.2 GOVERNMENT ORGANIZATION
10.3 HOSPITALS
10.4 ACADEMIC AND RESEARCH
10.5 OTHERS
11 MIDDLE EAST & AFRICA VIRTUAL REALITY MARKET, BY GEOGRAPHY
11.1 MIDDLE EAST AND AFRICA
11.1.1 SOUTH AFRICA
11.1.2 SAUDI ARABIA
11.1.3 UAE
11.1.4 EGYPT
11.1.5 ISRAEL
11.1.6 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 BAYER AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ALEMBIC PHARMACEUTICALS LIMITED
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALTIMMUNE
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWILLOW BIOLOGICS.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DEINOVE
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EMERGENT
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 ELUSYS THERAPEUTICS INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GC BIOPHARMA CORP.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 INDOCO REMEDIES LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGRATED BIOTHERAPEUTICS, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUPIN.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 PARATEK PHARMACEUTICALS, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 PORTON BIOPHARMA
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 SOLIGENIX
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-
TABLE 2 VACCINES IN DEVELOPMENT
TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-
TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-
TABLE 5 RECENT M&A IN ANTHRAX MARKET-
TABLE 6 ANTIBIOTICS MEDICINES
TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 48 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 49 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 52 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 53 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 55 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 56 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 58 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 59 MIDDLE EAST AND AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 63 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 64 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 67 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 68 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 70 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 71 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 73 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 74 MIDDLE EAST AND AFRICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 78 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 82 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 83 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 85 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 88 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 89 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 91 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 SOUTH AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 96 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 99 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 101 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 103 SOUTH AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 107 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 110 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 112 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 114 SOUTH AFRICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 118 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 121 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 123 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 125 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 126 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 127 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 SAUDI ARABIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 132 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 135 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 137 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 139 SAUDI ARABIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 143 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 146 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 148 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 150 SAUDI ARABIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 154 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 157 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 159 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 161 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 162 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 163 U.A.E ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 U.A.E CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 168 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 171 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 173 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 175 U.A.E PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 179 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 182 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 183 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 184 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 186 U.A.E INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 190 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 193 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 195 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 197 U.A.E ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 198 U.A.E ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 199 EGYPT ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 EGYPT CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 204 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 207 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 209 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 211 EGYPT PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 213 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 215 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 218 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 220 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 222 EGYPT INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 226 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 227 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 229 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 231 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 232 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 233 EGYPT ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 234 EGYPT ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 235 ISRAEL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 ISRAEL CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 238 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 240 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 243 ISRAEL ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 245 ISRAEL VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 247 ISRAEL PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 248 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 249 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 251 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 252 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 253 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 254 ISRAEL ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 255 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 256 ISRAEL VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 258 ISRAEL INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 259 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 261 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 262 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 263 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 264 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 265 ISRAEL ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 266 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 267 ISRAEL VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 268 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 269 ISRAEL ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 270 ISRAEL ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 271 REST OF MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET IN 2022 & 2029
FIGURE 14 MIDDLE EAST & AFRICA DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-
FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-
FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-
FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).
FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).
FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET
FIGURE 21 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, 2021
FIGURE 22 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)
FIGURE 24 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 26 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 28 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, 2021
FIGURE 30 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)
FIGURE 32 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 34 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 35 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 37 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
